Literature DB >> 23132211

Eosinophils in infection and intestinal immunity.

Simon P Hogan1, Amanda Waddell, Patricia C Fulkerson.   

Abstract

PURPOSE OF REVIEW: Inflammatory bowel diseases (IBDs, e.g., Crohn's disease and ulcerative colitis) are thought to be a consequence of an uncontrolled inflammatory response against luminal antigens, including commensal bacteria. The observed link between eosinophil levels and severity and remission rates in IBD has led to speculation that eosinophils may contribute to the antimicrobial inflammatory response in IBD. RECENT <br> FINDINGS: Eosinophils express the necessary cellular machinery (innate immune receptors, proinflammatory cytokines, antibacterial proteins, and DNA traps) to mount an efficient antibacterial response; however, the rapid decline in eosinophil numbers following acute systemic bacterial infection suggests a very limited role for eosinophils in bacterial responses. <br> SUMMARY: We describe the clinical evidence of eosinophil involvement in IBD, summarize the in-vitro and in-vivo evidence of eosinophil antibacterial activity and the biology of eosinophils focusing on eosinophil-mediated bactericidal mechanisms and the involvement of eosinophil-derived granule proteins in this response, and conceptualize the contribution of eosinophils to a response against commensal bacteria in IBD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23132211      PMCID: PMC3924957          DOI: 10.1097/MOG.0b013e32835ab29a

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  110 in total

1.  PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors.

Authors:  C Nerlov; T Graf
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

2.  Distinct C/EBP functions are required for eosinophil lineage commitment and maturation.

Authors:  C Nerlov; K M McNagny; G Döderlein; E Kowenz-Leutz; T Graf
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

3.  Infiltration of peroxidase-producing eosinophils into the lamina propria of patients with ulcerative colitis.

Authors:  H Nishitani; M Okabayashi; M Satomi; T Shimoyama; Y Dohi
Journal:  J Gastroenterol       Date:  1998-04       Impact factor: 7.527

4.  Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion.

Authors:  M Carlson; Y Raab; C Peterson; R Hällgren; P Venge
Journal:  Am J Gastroenterol       Date:  1999-07       Impact factor: 10.864

5.  Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin.

Authors:  C M Gelbmann; S Mestermann; V Gross; M Köllinger; J Schölmerich; W Falk
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

Review 6.  Food allergy. Part 1: immunopathogenesis and clinical disorders.

Authors:  H A Sampson
Journal:  J Allergy Clin Immunol       Date:  1999-05       Impact factor: 10.793

7.  Eosinophil peroxidase nitrates protein tyrosyl residues. Implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders.

Authors:  W Wu; Y Chen; S L Hazen
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

Review 8.  Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease.

Authors:  P Venge; J Byström; M Carlson; L Hâkansson; M Karawacjzyk; C Peterson; L Sevéus; A Trulson
Journal:  Clin Exp Allergy       Date:  1999-09       Impact factor: 5.018

9.  CD44 and CD69 represent different types of cell-surface activation markers for human eosinophils.

Authors:  K Matsumoto; J Appiah-Pippim; R P Schleimer; C A Bickel; L A Beck; B S Bochner
Journal:  Am J Respir Cell Mol Biol       Date:  1998-06       Impact factor: 6.914

10.  Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes.

Authors:  G Woerly; N Roger; S Loiseau; D Dombrowicz; A Capron; M Capron
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

View more
  34 in total

Review 1.  Innate immunity in disease.

Authors:  David E Elliott; Sana S Siddique; Joel V Weinstock
Journal:  Clin Gastroenterol Hepatol       Date:  2014-03-12       Impact factor: 11.382

Review 2.  T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.

Authors:  Mahmoud H Mosli; Jesus Rivera-Nieves; Brian G Feagan
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

3.  Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders.

Authors:  Robert D Pesek; Craig C Reed; Margaret H Collins; Amanda B Muir; Patricia C Fulkerson; Calies Menard-Katcher; Gary W Falk; Jonathan Kuhl; Adam Z Magier; Faria N Ahmed; Maureen Demarshall; Ankur Gupta; Jonathan Gross; Tokunbo Ashorobi; Christina L Carpenter; Jeffrey P Krischer; Nirmala Gonsalves; Ikuo Hirano; Jonathan M Spergel; Sandeep K Gupta; Glenn T Furuta; Marc E Rothenberg; Evan S Dellon
Journal:  Dig Dis Sci       Date:  2019-11-26       Impact factor: 3.199

4.  G2A Signaling Dampens Colitic Inflammation via Production of IFN-γ.

Authors:  S Courtney Frasch; Eóin N McNamee; Douglas Kominsky; Paul Jedlicka; Claudia Jakubzick; Karin Zemski Berry; Matthias Mack; Glenn T Furuta; James J Lee; Peter M Henson; Sean P Colgan; Donna L Bratton
Journal:  J Immunol       Date:  2016-07-08       Impact factor: 5.422

5.  Influenza A virus directly modulates mouse eosinophil responses.

Authors:  Kim S LeMessurier; Robert Rooney; Hazem E Ghoneim; Baoming Liu; Kui Li; Heather S Smallwood; Amali E Samarasinghe
Journal:  J Leukoc Biol       Date:  2020-05-09       Impact factor: 4.962

6.  Sex differences in IL-17 contribute to chronicity in male versus female urinary tract infection.

Authors:  Anna Zychlinsky Scharff; Matthieu Rousseau; Livia Lacerda Mariano; Tracy Canton; Camila Rosat Consiglio; Matthew L Albert; Magnus Fontes; Darragh Duffy; Molly A Ingersoll
Journal:  JCI Insight       Date:  2019-05-30

7.  Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.

Authors:  Erin M Kim; Cara Randall; Renee Betancourt; Staci Keene; Amy Lilly; Mark Fowler; Evan S Dellon; Hans H Herfarth
Journal:  Inflamm Bowel Dis       Date:  2020-07-17       Impact factor: 5.325

8.  Impact of eosinophil-peroxidase (EPX) deficiency on eosinophil structure and function in mouse airways.

Authors:  Caroline M Percopo; Julia O Krumholz; Elizabeth R Fischer; Laura S Kraemer; Michelle Ma; Karen Laky; Helene F Rosenberg
Journal:  J Leukoc Biol       Date:  2018-10-04       Impact factor: 4.962

9.  Microbiota-Regulated IL-25 Increases Eosinophil Number to Provide Protection during Clostridium difficile Infection.

Authors:  Erica L Buonomo; Carrie A Cowardin; Madeline G Wilson; Mahmoud M Saleh; Patcharin Pramoonjago; William A Petri
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

10.  IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis.

Authors:  J C Martin; G Bériou; M Heslan; C Bossard; A Jarry; A Abidi; P Hulin; S Ménoret; R Thinard; I Anegon; C Jacqueline; B Lardeux; F Halary; J-C Renauld; A Bourreille; R Josien
Journal:  Mucosal Immunol       Date:  2015-09-02       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.